ProfileGDS5678 / 1444105_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 39% 37% 37% 37% 36% 39% 40% 37% 37% 37% 37% 38% 38% 38% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9338539
GSM967853U87-EV human glioblastoma xenograft - Control 22.8458337
GSM967854U87-EV human glioblastoma xenograft - Control 32.8544937
GSM967855U87-EV human glioblastoma xenograft - Control 42.7861137
GSM967856U87-EV human glioblastoma xenograft - Control 52.7665436
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.983339
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9741940
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8327537
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8312937
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8231437
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8476237
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8270138
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8773938
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8516238